BIO EUROPE SPRING 2022
We hope you enjoyed the BIO-EUROPE SPRING® 2022 virtual event, where our Subject Matter Experts provided key insights on the following hot topic:
Next generation biologics – manufacturing and supply strategies to accelerate time to market
Recent advances in technology have seen the development of many new types of biologics that have been particularly effective at targeting specific diseases. Increased complexities may lead to technical challenges resulting in longer CMC development timelines, a delay to clinical trials, and delayed commercial launches.
- Best practices in managing complexities associated with next generation biologics development
- Formulation development and purification strategies to increase throughput, reduce operating costs and development timelines
- How to scale projects from early development through to large scale biologics manufacturing via 2k, 5K and up to 12.5K bioreactor technologies
- Applying a streamlined process, end-to-end, to accelerate time to market
Vice President and General Manager, Lengnau, Switzerland, Thermo Fisher Scientific
Sr. Director and General Manager, Groningen, The Netherlands, Thermo Fisher Scientific
Should we have missed out on connecting at BIO-EUROPE SPRING® 2022, reach out to us to find out more about how we help pharma and new and emerging biotech companies turn pharmaceutical possibilities into realities and get to market faster.
